The current production of adeno-associated virus-based gene therapy products heavily relies on cell-based manufacturing, which is inherently restrictive and inefficient. To address this issue, the project aims to establish a platform for producing cell-free gene therapy viral vectors using micro-fluidic flow chemistry. This approach will offer a more precise, scalable, and cost-effective process of gene therapy manufacturing. In addition, it will ensure a safer and more predictable product for usage in human subjects by eliminating contaminants derived from the cell-based origin. The strategy of the project involves producing viral components using cell-free systems, which will then be combined in a microfluidic flow cell to facilitate the autoassembly of viral particles. This flow cell will precisely regulate the crucial factors necessary for viral assembly in a system that reduces product manipulation for operators and manufacturing cost.